A Study of CNTO 136 (Sirukumab), Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Disease-Modifying Antirheumatic Drug (DMARD) Therapy (SIRROUND-D)

NCT01604343 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1670

Enrollment

INDUSTRY

Sponsor class

Conditions

Arthritis, Rheumatoid

Interventions

DRUG: Placebo
DRUG: Placebo
DRUG: Sirukumab
DRUG: Sirukumab
DRUG: Sirukumab

Sponsor

Janssen Research & Development, LLC

Collaborators

[object Object]